Little House Capital LLC Buys 10,007 Shares of Johnson & Johnson (NYSE:JNJ)

Little House Capital LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 53.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 28,711 shares of the company's stock after acquiring an additional 10,007 shares during the period. Johnson & Johnson accounts for about 1.3% of Little House Capital LLC's portfolio, making the stock its 23rd largest position. Little House Capital LLC's holdings in Johnson & Johnson were worth $4,761,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $4,390,037,000. Raymond James Financial Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $1,339,878,000. GAMMA Investing LLC grew its holdings in shares of Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Janus Henderson Group PLC boosted its position in Johnson & Johnson by 134.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after purchasing an additional 4,559,147 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.08 during mid-day trading on Wednesday, reaching $155.84. The stock had a trading volume of 1,492,591 shares, compared to its average volume of 8,020,336. The stock has a market capitalization of $374.95 billion, a P/E ratio of 17.31, a P/E/G ratio of 2.31 and a beta of 0.41. The firm has a 50 day moving average price of $153.63 and a two-hundred day moving average price of $153.87. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on JNJ shares. Bank of America cut their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Morgan Stanley lifted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.